Biotech · Private company · Baltimore, MD, US
AgeneBio
Track this companyFree. Adds AgeneBio to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- AGB101 220 mg tabletPhase 3 · Mild Cognitive ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- AGB101Phase 2 · Mild Cognitive ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older AdultsPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 17, 2025ClinicalTrials.gov NCT06919926 · fetched Nov 12, 2026
- Clinical Trial of AGB101 for Mild Cognitive ImpairmentPHASE2 · WITHDRAWN · started Dec 3, 2024ClinicalTrials.gov NCT05986721 · fetched Nov 12, 2026
- Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related PsychosisPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 28, 2023ClinicalTrials.gov NCT05824728 · fetched Nov 12, 2026
- Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's DiseasePHASE2_PHASE3 · COMPLETED · started Dec 13, 2018ClinicalTrials.gov NCT03486938 · fetched Nov 12, 2026
NIH awards4
- Preclinical and early clinical development of a GABA-A a5 PAMFiscal year 2026 · $203.5KNIH RePORTER 3U01AG074950-04S1 · fetched Nov 12, 2026
- Preclinical and early clinical development of a GABA-A a5 PAMFiscal year 2025 · $268.4KNIH RePORTER 3U01AG074950-03S1 · fetched Nov 12, 2026
- Preclinical and early clinical development of a GABA-A a5 PAMFiscal year 2025 · $1.1MNIH RePORTER 5U01AG074950-04 · fetched Nov 12, 2026
- Preclinical and early clinical development of a GABA-A a5 PAMFiscal year 2024 · $1.1MNIH RePORTER 5U01AG074950-03 · fetched Nov 12, 2026